Green­Light re­ceives buy­out of­fer; Apol­lomics com­pletes SPAC merg­er

RNA biotech Green­Light Bio­sciences has been hand­ed an of­fer for po­ten­tial ac­qui­si­tion.

Green­Light said in a re­lease that it has re­ceived a non-bind­ing “in­di­ca­tion of in­ter­est” from Fall Line En­durance Fund to ac­quire Green­Light’s cap­i­tal stock for $0.60 per share in cash. The re­lease said any po­ten­tial agree­ment be­tween the two par­ties would de­pend on cer­tain con­di­tions.

Through a spe­cial com­mit­tee, the biotech will eval­u­ate the of­fer but added there’s no cer­tain­ty a deal will go for­ward. Green­Light will al­so not make any more an­nounce­ments un­til a deal comes through or “oth­er­wise de­ter­mines” a state­ment is nec­es­sary.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN